Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
$1.28
$0.75
$26.18
$7.26M1.27811,695 shs119,800 shs
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
$3.35
+5.0%
$2.96
$2.07
$4.20
$107.90M0.39104,338 shs38,261 shs
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$1.70
-1.7%
$1.68
$1.15
$3.50
$11.89M-0.3422,859 shs3,539 shs
Otonomy, Inc. stock logo
OTIC
Otonomy
$0.01
$0.06
$0.01
$2.54
$582K1.54937,525 shsN/A
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
$1.30
$1.30
$0.25
$1.40
$70.12M1.32515,333 shsN/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
+5.02%-0.89%+18.79%+32.41%+48.23%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-0.29%-6.03%-3.13%+24.09%-45.86%
Otonomy, Inc. stock logo
OTIC
Otonomy
0.00%0.00%0.00%0.00%0.00%
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
2.6964 of 5 stars
3.63.00.00.01.13.30.0
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
3.2061 of 5 stars
3.04.00.04.60.00.01.3
Otonomy, Inc. stock logo
OTIC
Otonomy
N/AN/AN/AN/AN/AN/AN/AN/A
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
0.00
N/AN/AN/A
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
3.25
Buy$9.00168.66% Upside
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
2.00
Hold$5.00194.12% Upside
Otonomy, Inc. stock logo
OTIC
Otonomy
0.00
N/AN/AN/A
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest OTIC, ADMP, ANIX, NERV, and ZYNE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/10/2025
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/29/2025
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
4/10/2025
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
$4.76M0.00N/AN/A($1.26) per share0.00
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
$210K513.83N/AN/A$0.46 per share7.28
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/A$0.21 per share8.28($3.67) per shareN/A
Otonomy, Inc. stock logo
OTIC
Otonomy
$130K4.48N/AN/A$0.97 per share0.01
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
N/AN/AN/AN/A$1.01 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
-$26.48MN/A0.00N/AN/A-502.73%-420.53%-256.87%N/A
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
-$12.55M-$0.38N/AN/AN/A-68.17%-60.38%9/5/2025 (Estimated)
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$1.44M$0.822.07N/AN/AN/A-20.68%15.73%8/5/2025 (Estimated)
Otonomy, Inc. stock logo
OTIC
Otonomy
-$51.18M-$0.77N/AN/AN/A-137.86%-68.50%N/A
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
-$35.04M-$0.80N/AN/AN/AN/A-90.03%-72.62%N/A

Latest OTIC, ADMP, ANIX, NERV, and ZYNE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/3/2025Q2 2025
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
-$0.10-$0.09+$0.01-$0.09N/AN/A
5/13/2025Q1 2025
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$1.07-$0.50+$0.57-$0.50N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
N/AN/AN/AN/AN/A
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
N/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/AN/A
Otonomy, Inc. stock logo
OTIC
Otonomy
N/AN/AN/AN/AN/A
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
N/A
0.23
0.19
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
N/A
8.89
8.89
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/A
9.21
9.21
Otonomy, Inc. stock logo
OTIC
Otonomy
N/A
1.74
1.74
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
N/A
3.43
3.43

Institutional Ownership

CompanyInstitutional Ownership
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
38.55%
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
29.13%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
34.56%
Otonomy, Inc. stock logo
OTIC
Otonomy
41.23%
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
11.23%
CompanyEmployeesShares OutstandingFree FloatOptionable
Adamis Pharmaceuticals Co. stock logo
ADMP
Adamis Pharmaceuticals
119.36 million9.24 millionOptionable
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
532.21 million24.06 millionOptionable
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
96.99 million6.39 millionNot Optionable
Otonomy, Inc. stock logo
OTIC
Otonomy
5168.53 million67.78 millionOptionable
Zynerba Pharmaceuticals, Inc. stock logo
ZYNE
Zynerba Pharmaceuticals
2553.94 million46.91 millionOptionable

Recent News About These Companies

Harmony Biosciences: If It Ain't Broke
US Penny Stocks To Watch In October 2024
Discover 3 US Penny Stocks With Market Caps Over $70M
GW Pharma's cannabis-derived epilepsy drug approved in EU
20 Countries With Highest Rate of Epilepsy

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Adamis Pharmaceuticals stock logo

Adamis Pharmaceuticals NASDAQ:ADMP

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory disease. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company is headquartered in San Diego, California.

Anixa Biosciences stock logo

Anixa Biosciences NASDAQ:ANIX

$3.35 +0.16 (+5.02%)
Closing price 07/3/2025 03:57 PM Eastern
Extended Trading
$3.28 -0.08 (-2.24%)
As of 07/3/2025 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Minerva Neurosciences stock logo

Minerva Neurosciences NASDAQ:NERV

$1.70 -0.03 (-1.73%)
As of 07/3/2025 01:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Otonomy stock logo

Otonomy NASDAQ:OTIC

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

Zynerba Pharmaceuticals stock logo

Zynerba Pharmaceuticals NASDAQ:ZYNE

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.